CD40LG and hematologic disorder: Anti-HEV IgM seroprevalence, as determined by the Euroimmun assay, was 1% (1/66) in oncological patients, with a subgroup distribution of 2.5% in those with hematological malignancies and 0% in patients with solid tumors.